Clinical Trials Logo

Meningioma, Malignant clinical trials

View clinical trials related to Meningioma, Malignant.

Filter by:
  • None
  • Page 1

NCT ID: NCT06275919 Not yet recruiting - Clinical trials for Meningioma, Malignant

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)

MIRAGE
Start date: June 2024
Phase: Phase 2
Study type: Interventional

The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent grade II or III meningiomas. Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome. Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas. Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p<0.05) for Regorafenib treated mice. Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.

NCT ID: NCT04728568 Recruiting - Clinical trials for Meningioma, Malignant

Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

This research study is studying a drug as a possible treatment for High Grade Meningioma.